Latest Insider Transactions at Verve Therapeutics, Inc. (VERV)
This section provides a real-time view of insider transactions for Verve Therapeutics, Inc. (VERV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Verve Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Verve Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2022
|
Fmr LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
18,810
-2.38%
|
$282,150
$15.21 P/Share
|
|
Jun 29
2022
|
Fmr LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
34,409
-2.09%
|
$516,135
$15.55 P/Share
|
|
May 12
2022
|
Burt A Adelman |
BUY
Open market or private purchase
|
Indirect |
10,000
+34.84%
|
$120,000
$12.15 P/Share
|
|
Mar 18
2022
|
Sekar Kathiresan Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
69,674
+12.73%
|
$139,348
$2.87 P/Share
|
|
Mar 15
2022
|
Burt A Adelman |
BUY
Open market or private purchase
|
Indirect |
4,000
+31.5%
|
$84,000
$21.38 P/Share
|
|
Mar 09
2022
|
Fmr LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,971
-0.48%
|
$115,159
$29.01 P/Share
|
|
Feb 09
2022
|
Fmr LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
13,190
-1.56%
|
$382,510
$29.46 P/Share
|
|
Feb 01
2022
|
Fmr LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
35,574
-4.05%
|
$1,031,646
$29.04 P/Share
|
|
Jan 27
2022
|
Fmr LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,983
-0.51%
|
$260,507
$29.64 P/Share
|
|
Jan 26
2022
|
Fmr LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
149,853
-5.02%
|
$4,495,590
$30.92 P/Share
|
|
Jan 04
2022
|
Sekar Kathiresan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,870
-0.46%
|
$72,930
$39.9 P/Share
|
|
Jan 04
2022
|
Sekar Kathiresan Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,870
+0.46%
|
$1,870
$1.39 P/Share
|
|
Dec 28
2021
|
Sekar Kathiresan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,693
-1.62%
|
$261,027
$39.9 P/Share
|
|
Dec 28
2021
|
Sekar Kathiresan Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,693
+1.59%
|
$6,693
$1.39 P/Share
|
|
Dec 27
2021
|
Sekar Kathiresan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
42,000
-3.16%
|
$1,722,000
$41.16 P/Share
|
|
Dec 27
2021
|
Sekar Kathiresan Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
42,000
+8.56%
|
$42,000
$1.39 P/Share
|
|
Dec 23
2021
|
Sekar Kathiresan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
57,000
-12.3%
|
$2,223,000
$39.9 P/Share
|
|
Dec 23
2021
|
Sekar Kathiresan Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
57,000
+10.95%
|
$57,000
$1.39 P/Share
|
|
Dec 22
2021
|
Sekar Kathiresan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
57,000
-3.19%
|
$2,166,000
$38.63 P/Share
|
|
Dec 22
2021
|
Sekar Kathiresan Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
57,000
+10.95%
|
$57,000
$1.39 P/Share
|
|
Dec 22
2021
|
Andrew Bellinger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,000
-34.82%
|
$570,000
$38.46 P/Share
|
|
Dec 22
2021
|
Andrew Bellinger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+42.86%
|
$15,000
$1.48 P/Share
|
|
Dec 02
2021
|
Burt A Adelman |
BUY
Open market or private purchase
|
Indirect |
4,700
+50.0%
|
$145,700
$31.34 P/Share
|
|
Dec 02
2021
|
Andrew D. Ashe |
BUY
Open market or private purchase
|
Direct |
4,000
+2.29%
|
$128,000
$32.1 P/Share
|
|
Jun 21
2021
|
Arch Venture Partners X, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,508,809
+50.0%
|
-
|
|
Jun 21
2021
|
Broad Institute, Inc. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
387,830
+32.38%
|
-
|
|
Jun 21
2021
|
Fmr LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,037,294
+48.27%
|
-
|
|
Jun 21
2021
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
275,000
+21.84%
|
$5,225,000
$19.0 P/Share
|
|
Jun 21
2021
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
709,224
+50.0%
|
-
|
|
Jun 21
2021
|
Beam Therapeutics Inc. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
270,895
+33.12%
|
-
|
|
Jun 21
2021
|
Redmile Group, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,050,000
+35.16%
|
$19,950,000
$19.0 P/Share
|
|
Jun 21
2021
|
Redmile Group, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
886,530
+50.0%
|
-
|
|
Jun 21
2021
|
Casdin Partners Master Fund, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,100,000
+31.27%
|
$20,900,000
$19.0 P/Share
|
|
Jun 21
2021
|
Casdin Partners Master Fund, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,317,596
+34.53%
|
-
|
|
Jun 21
2021
|
Casdin Private Growth Equity Fund, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
620,571
+50.0%
|
-
|
|
Jun 21
2021
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,495,571
+40.8%
|
-
|
|
Jun 21
2021
|
Krishna Yeshwant |
BUY
Conversion of derivative security
|
Indirect |
10,793,414
+36.34%
|
-
|
|
Jun 21
2021
|
Gv 2019 Gp, L.L.C. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
4,472,509
+29.51%
|
-
|
|
Jun 21
2021
|
Gv 2017 Gp, L.L.C. |
BUY
Conversion of derivative security
|
Indirect |
6,320,905
+50.0%
|
-
|
|
Jun 21
2021
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
350,000
+30.61%
|
$6,650,000
$19.0 P/Share
|
|
Jun 21
2021
|
Novo Holdings > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
443,265
+50.0%
|
-
|
|
Jun 21
2021
|
Logos Global Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
370,000
+50.0%
|
$7,030,000
$19.0 P/Share
|
|
Jun 21
2021
|
Logos Global Management LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
443,265
+50.0%
|
-
|
|
Jun 21
2021
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
709,224
+50.0%
|
-
|
|
Jun 21
2021
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
370,000
+28.54%
|
$7,030,000
$19.0 P/Share
|
|
Jun 21
2021
|
Sekar Kathiresan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+0.61%
|
$47,500
$19.0 P/Share
|
|
Jun 21
2021
|
Andrew Bellinger Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$95,000
$19.0 P/Share
|
|
Jun 21
2021
|
Margaret Beaudoin Vice President, Finance |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$19,000
$19.0 P/Share
|